Pierre Fabre Taps XtalPi’s AI and Robotics for Drug Discovery

Laboratoires Pierre Fabre and XtalPi announced on November 9, 2026 an agreement to discover novel small-molecule clinical candidates across multiple research programs. XtalPi will contribute integrated AI capabilities and a robotics platform, while Pierre Fabre will select and advance compounds in oncology, potentially dermatology, and rare diseases. The partners are directing that work toward challenging and historically hard-to-drug targets, which they associate with significant unmet medical need and substantial opportunities for innovative drug discovery.

That focus gives context to the companies’ stated goal of accelerating the identification of high-quality clinical candidates. The emphasis on both quality and speed means the intended output is compounds strong enough to become clinical candidates in areas where discovery has been difficult. XtalPi will handle de novo design, meaning the creation of new molecular structures, and deliver novel small-molecule therapeutics against undisclosed targets.

This places its integrated AI capabilities and robotics platform at the front end of the partnered discovery process, with the resulting molecules moving into Pierre Fabre’s selection work. Pierre Fabre will apply…